Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.

Molecular pharmacology - 1 Jul 2019

Cronise Kathryn E, Hernandez Belen G, Gustafson Daniel L, Duval Dawn L

Abstract excerpt

Transitional cell carcinoma (TCC) of the bladder comprises 2% of diagnosed canine cancers. TCC tumors are generally inoperable and unresponsive to traditional chemotherapy, indicating a need for more effective therapies. BRAF, a kinase in the mitogen-activated protein kinase (MAPK) pathway, is mutated in 70% of canine TCCs. In this study, we use BRAF mutant and wild-type TCC cell lines to characterize the role of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Dog Diseases
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HT29 Cells

Share to Pyridones

Share to Pyrimidinones

Share to Quinazolines

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 31048548
DOI: 10.1124/mol.119.115808
PMCID: PMC13102104

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.PMID 31048548Read ↗

Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.Semantic proximity Read ↗

Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.Semantic proximity Read ↗

Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation.Semantic proximity Read ↗

Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.Semantic proximity Read ↗

Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).Semantic proximity Read ↗

Establishment of a BRAF V595E-mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer.Semantic proximity Read ↗

Comparative Aspects of BRAF Mutations in Canine CancersSemantic proximity Read ↗

BRAF Mutations in Canine Cancers.Semantic proximity Read ↗

Management of transitional cell carcinoma of the urinary bladder in dogs: a review.Semantic proximity Read ↗

Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome SequencingSemantic proximity Read ↗

Anti‐tumour effect of lapatinib in canine transitional cell carcinoma cell linesSemantic proximity Read ↗

A comparative meta and <i>in silico</i> analysis of differentially expressed genes and proteins in canine and human bladder cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.